Defactinib (INN, codenamed VS-6063) is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and...
4 KB (231 words) - 00:58, 9 June 2022
officer (CEO) of Verastem Oncology. Their leading investigational drug is defactinib (VS-6063), is a small-molecule focal adhesion kinase (FAK) inhibitor designed...
9 KB (726 words) - 12:52, 13 July 2024
clinical trials in 2014 were: VS-6062 (PF 562,271), VS-6063 (PF-04554878 defactinib) and VS-4718 (PND-1186) (all three are ATP-competitive kinase inhibitors)...
41 KB (4,724 words) - 09:43, 11 December 2023